CTRI/2018/08/015269尚未招募未知
A multicentre, open label, balanced, randomized, two-treatment, four-period, two-sequence, full replicate crossover, single dose, oral bioequivalence study of Capecitabine 500 mg Film-Coated Tablets of Onko Ilaç San. ve Tic. A.S. with Xeloda 500mg Film-Coated Tablets (Capecitabine) marketed by Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden City, AL71TW, United Kingdom following a single oral dose of 2000mg (4x500mg) in adult human cancer patients under fed conditions. - CBCC/2018/001
Onko Ila San ve Tic AS0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Willing and able to provide voluntary informed consent and to follow the protocol requirements.
- •2.Male or Female aged 18 to 65 years (both inclusive) having Body Mass Index (BMI) at least 17.00 calculated as weight in kg/height in m2.
- •3.Patients having Body Surface Area between 1.27-1.92 m2 (Both inclusive) measured as per the Dubois formula.
- •4.Patients with histopathologically/cytologically confirmed colon, colorectal or breast cancer.
- •5.Patients with Dukesâ?? C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred.
- •Patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred.
- •Patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
- •6.Patients requiring a daily dose of Capecitabine monotherapy and stabilized at least on one cycle of Capecitabine chemotherapy on twice daily dosing at a dose of 1250 mg/m2 for 14 days.
- •7.Eastern Cooperative Oncology Group (ECOG) performance status <= 2.
- •8.Acceptable hematology status:
- •a.Hemoglobin >= 9 g/dL
- •b.Absolute neutrophil count (ANC) >= 1500 cells/mm3
- •c.Platelet count >= 100,000 cells/mm3
- •9.Acceptable liver function:
- •a.Alanine aminotransferase (ALT) <= 2.5 X ULN (<=5 x ULN if liver metastases present)
- •b.Aspartate aminotransferase (AST) <= 2.5 X ULN (<=5 x ULN if liver metastases present)
- •c.Bilirubin <= 1.5 X ULN
- •d.Alkaline phosphatase <= 2.5 X ULN (<=5 x ULN if liver metastases present)
- •10.Patients with Creatinine clearance >= 60 mL/minute
- •11.Patients with life expectancy of at least 6 months at the time of enrolment.
- •12.Female patients with negative serum pregnancy test at screening and negative urine pregnancy test at Day 0.
- •13.Patients who agree to use adequate contraception (eg, hormonal, chemical, double-barrier, or abstinence) while in the study.
- •14.No history of addiction to any recreational drug or drug dependence or alcohol addiction.
排除标准
- •1.Known hypersensitivity or contraindication to fluoropyrimidine therapy.
- •2.Known hypersensitivity or contraindication to Ondansetron.
- •3.History or presence of any uncontrolled debilitating systemic disease (e.g. cardiovascular disease, hypertension, diabetes mellitus etc.).
- •4.Known CNS metastasis.
- •5.Major surgical procedure (including periodontal) within 28 days of first dose of Investigational Product.
- •6.Surgical or other non-healing wounds.
- •7.Patients with positive serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), or Human Immunodeficiency Virus (HIV).
- •8.Patients with positive urine screen for Drugs of Abuse.
- •9.History of other malignancies in the last 5 years (except in situ cancer or basal or squamous cell skin cancer).
- •10.Has not recovered to Grade 0 or 1 toxicity from previous anticancer treatments or previous investigational agents. Exceptions are alopecia (any grade is acceptable), fatigue (Grade 2 is acceptable), and peripheral neuropathy (stable Grade 2 is acceptable) (Per National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], V5.0).
- •11.Participation in any clinical study within 90 days before the first dose of Investigational Product.
- •12.Donation of blood (1 unit or 350 ml) within 90 days prior to receiving the first dose of investigational product for the current study.
- •13.Patients with difficulties in swallowing and retaining oral medications.
- •14.Patients taking any of the Cytochrome P450 2C9 substrates.
- •15.Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study including but not limited to cirrhosis or psychiatric illness/social situations that would limit adherence to study requirements.
- •16.Any other condition(s) which could significantly interfere with Protocol compliance including, but not limited to, dementia, psychosis, cognitive impairment, altered mental status, or other major psychiatric disorder.
- •17.Pregnant or breastfeeding.
研究者
相似试验
已完成
不适用
Bioequivalence study of Risperidone in patients with schizophrenia or bipolar I disorder.CTRI/2018/09/015704Qilu Pharmaceutical Co Ltd24
进行中（未招募）
不适用
A multicenter, open label, balanced, randomized, two treatment, two-period crossover, multi-dose, steady state, bioequivalence study of Nevirapine 400 mg prolonged release tablets, compared to Viramune 400 mg prolonged release tablets in adult HIV1 infected patients.CTRI/2015/10/006244Amneal Pharmaceuticals Company GmbH
招募中
不适用
A multicenter, open label,patients with metastatic breast cancer patients under fed (standardized light meal) condition.CTRI/2022/06/043101TTY Biopharm Company Ltd
已完成
不适用
Bioequivalence study of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Dr. Reddyâ??s Laboratories, with that of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL of Sun Pharmaceutical Ind., in ovarian cancer patientsCTRI/2014/06/004703Dr Reddys Laboratories Limited60
进行中（未招募）
不适用
Study of Paliperidone Palmitate injection 156mg/mL with INVEGA SUSTENNA® Injectable Suspension 156mg/mL in subjects with schizophrenia.CTRI/2020/05/025244Qilu Pharmaceutical Co Ltd